quinazolines has been researched along with Peritoneal Carcinomatosis in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (37.50) | 29.6817 |
| 2010's | 19 (59.38) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, G; Gong, Q; Liang, X; Liu, J; Song, C; Wang, R; Wang, X | 1 |
| Cai, G; Cai, S; Chen, Y; Li, Y; Liang, X; Liu, J; Meng, X; Qi, Y; Qiu, C; Xu, Y; Zheng, H | 1 |
| Abbruzzese, JL; Carlson, P; Fogelman, DR; George, B; Javle, M; Khalil, MA; Overman, M; Qiao, W; Varadhachary, G; Wolff, RA | 1 |
| Buck, M; Casado, A; Coens, C; Colombo, N; Curé, H; Despierre, E; Favier, L; Ferrero, A; Green, J; Hall, M; Jimeno, A; Joly, F; Katsaros, D; Lesoin, A; Marth, C; Pujade-Lauraine, E; Ray-Coquard, I; Reed, NS; Reinthaller, A; Steer, CB; Vergote, IB | 1 |
| Kurzrock, R; Parker, BA; Schwab, R; Yan, M | 1 |
| Anderson, GL; Bonebrake, AJ; Chambers, SK; Coleman, RL; Delmore, JE; Hu, W; Markman, M; Moon, J; Sood, AK | 1 |
| Casado, A; Coens, C; Jimeno, A; Vergote, I | 1 |
| Freidlin, B; Korn, EL | 1 |
| Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY | 1 |
| Gao, Q; Gong, C; Jin, P; Liu, Y; Ma, D; Wei, X; Xu, S; Yang, Z; Zhang, T; Zhou, X | 1 |
| Biagi, J; Fleming, GF; Hirte, H; Ivy, SP; Lheureux, S; McGill, S; Morgan, R; Oza, AM; Sugimoto, A; Wang, L | 1 |
| Berkenblit, A; Berlin, S; Campos, S; Cannistra, SA; Hill, M; Horowitz, N; Humphreys, BD; Ivy, P; Krasner, C; Lee, H; Lee, J; Matulonis, UA; Penson, RT; Roche, M; Sullivan, L; Tran, C; Tyburski, K; Whalen, C; Zarwan, C | 1 |
| Bougnoux, P; Carrasco, AT; Fumoleau, P; Joly, F; Kerbrat, P; Lhommé, C; Pautier, P; Petit, T; Ringeisen, F; Rixe, O | 1 |
| Blank, SV; Chen, HX; Christos, P; Curtin, JP; Goldman, N; Liebes, L; Muggia, FM; Runowicz, CD; Sparano, JA | 1 |
| Carreau, JH; Foster, JM; Gatalica, Z; Govindarajan, V; Loggie, BW; Nath, SK; Radhakrishna, U; Sharma, P | 1 |
| Goff, B; Holmberg, LA; Veljovich, D | 1 |
| Dakhilm, SR; Haluska, P; Hartmann, LC; Keeney, GL; Moore, DF; Oberg, AL; Peethambaram, PP; Rowland, KM; Weroha, SJ; Ziegler, KL | 1 |
| Berardi, S; Caravatta, L; Cellini, N; Deodato, F; Di Filippo, L; Fabrizio, G; Ingrosso, M; Macchia, G; Massaccesi, M; Morganti, AG; Pacelli, F; Padula, GD; Picardi, V; Ridolfini, MP; Tambaro, R; Valentini, V | 1 |
| Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM | 1 |
| Armstrong, DK; Carolla, RL; Fischer, EG; Garcia, AA; Godwin, AK; Lankes, HA; Leslie, KK; Liepman, MK; Mannel, RS; Sill, MW; Spirtos, NM | 1 |
| Ashai, A; Avital, I; Hassan, R; Kalra, N; Raffeld, M; Xi, L; Zhang, J | 1 |
| Barthélemy, P; Daniel, C; Doubre, H; Fandi, A; Fizazi, K; Le Chevalier, T; Riviere, A; Robert, L; Ruffié, P; Viala, J | 1 |
| Nakata, H; Ohsaki, Y; Tuji, T | 1 |
| Chau, I; Cunningham, D; Hill, M; Katopodis, R; Middleton, G; Norman, AR; Oates, JR; Ross, PJ; Stewart, G; Topham, C; Waters, JS | 1 |
| Govindan, R; Green, MR; Herndon, JE; Kindler, HL; Kratzke, RA; Niehans, GA; Vollmer, R; Watson, D | 1 |
| Arao, T; Koizumi, F; Nishio, K; Shiratori, Y; Takeda, M; Takigahira, M; Yanagihara, K | 1 |
| Arciero, CA; Chen, X; Darcy, KM; Decesare, SL; Godwin, AK; Lee, RB; Lewandowski, G; Schilder, RJ; Sill, MW; Wu, H | 1 |
| Garcia-Carbonero, R; Paz-Ares, L | 1 |
| Perng, RP; Su, HT; Tsai, CM | 1 |
| Faoro, L; Fleming, GF; Friberg, G; Kasza, K; Morgan, RJ; Nimeiri, HS; Oza, AM; Salgia, R; Stadler, WM; Vokes, EE | 1 |
| Carty, K; Gabra, H; Gore, M; Guastalla, JP; Kaye, S; Lauraine, EP; Paul, J; Rustin, G; Vasey, PA; Wilson, R | 1 |
| Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M | 1 |
1 review(s) available for quinazolines and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Systemic chemotherapy in the management of malignant peritoneal mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Peritoneal Neoplasms; Quinazolines; Thiophenes; Vinblastine; Vinorelbine | 2006 |
18 trial(s) available for quinazolines and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Ca
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Europe; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Maintenance Chemotherapy; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Signal Transduction; Watchful Waiting | 2014 |
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Quinazolines; Taxoids; Treatment Outcome | 2014 |
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines | 2015 |
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Survival Analysis; Treatment Outcome | 2009 |
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gefitinib; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines | 2010 |
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Gene Amplification; Genes, erbB-1; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Young Adult | 2010 |
Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Taxoids | 2011 |
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Receptor, ErbB-2; Survival Rate; Topotecan | 2011 |
Neoadjuvant accelerated concomitant boost radiotherapy and multidrug chemotherapy in locally advanced rectal cancer: a dose-escalation study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Quinazolines; Rectal Neoplasms; Thiophenes; Treatment Outcome | 2012 |
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Disease-Free Survival; ErbB Receptors; Female; Humans; Ki-67 Antigen; Lapatinib; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polymorphism, Genetic; Quinazolines | 2012 |
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Mesothelioma; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Pleural Neoplasms; Prognosis; Quinazolines; Survival Rate; Thiophenes; Treatment Outcome | 2003 |
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate; Thiophenes; Thymidylate Synthase; Treatment Outcome | 2004 |
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Male; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Pleural Neoplasms; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2005 |
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Catalytic Domain; Cloning, Molecular; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunohistochemistry; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Polymerase Chain Reaction; Protein Structure, Tertiary; Quinazolines; Recurrence; Time Factors; Treatment Outcome | 2005 |
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Selection; Peritoneal Neoplasms; Quinazolines; Safety; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Taxoids | 2008 |
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Quinazolines; Salvage Therapy; Secondary Prevention; Thiophenes; Treatment Outcome | 2002 |
13 other study(ies) available for quinazolines and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Hyperthermic intraperitoneal chemotherapy with recombinant mutant human TNF-α and raltitrexed in mice with colorectal-peritoneal carcinomatosis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Colorectal Neoplasms; HCT116 Cells; Humans; Injections, Intraperitoneal; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Peritoneal Neoplasms; Quinazolines; Recombinant Proteins; Thiophenes; Tumor Necrosis Factor-alpha | 2020 |
A study of peritoneal metastatic xenograft model of colorectal cancer in the treatment of hyperthermic intraperitoneal chemotherapy with Raltitrexed.
Topics: Absorption, Physiological; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Half-Life; Hot Temperature; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Mice, Nude; Peritoneal Neoplasms; Quinazolines; Random Allocation; Thiophenes; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
HER2 aberrations in cancer: implications for therapy.
Topics: Ado-Trastuzumab Emtansine; Adult; Afatinib; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Maytansine; Molecular Targeted Therapy; Mutation; Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Up-Regulation; Uterine Cervical Neoplasms | 2014 |
Reply to B. Freidlin et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Transparency in interim monitoring.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Quinazolines; Republic of Korea; Retrospective Studies; Survivors; Treatment Outcome | 2014 |
Co-targeting EGFR and Autophagy Impairs Ovarian Cancer Cell Survival during Detachment from the ECM.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Extracellular Matrix; Female; Humans; Mice, SCID; Molecular Targeted Therapy; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Spheroids, Cellular; Tumor Cells, Cultured; Tyrphostins; Xenograft Model Antitumor Assays | 2015 |
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.
Topics: DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mesothelioma; Mutation; Peritoneal Neoplasms; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Mutation; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines | 2012 |
[A case of peritonitis carcinomatosa of pulmonary adenocarcinoma in which gefitinib was effective].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Ascitic Fluid; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Peritonitis; Quinazolines | 2004 |
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.
Topics: Biomarkers, Tumor; Carcinoma, Signet Ring Cell; Gene Expression Profiling; Humans; Neoplasm Metastasis; Neoplasms, Experimental; Peritoneal Neoplasms; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |
Peritoneal carcinomatosis in lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Quinazolines; Retrospective Studies; Taiwan | 2008 |